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Abstract: The healing of large bone defects can be
improved by osteogenic bone graft substitutes, due to
growth factor inclusion. A sustained release of these
growth factors provides more efficient bioactivity when
compared with burst release and might reduce the dose
required for bone regeneration, which is desirable for
socioeconomical and safety reasons. In this study, we
compared different rhBMP-2 loadings in a sustained
release system of CaP cement and PLGA-microparticles
and were able to couple kinetic to biological activity data.
Fifty-two rats received a critical-size cranial defect, which
was left open or filled with the cement composites. The
implants consisted of plain, high, and five-fold lower dose
rhBMP-2 groups. Implantation time was 4 and 12 weeks.
Longitudinal in vivo release was monitored by scinti-
graphic imaging of 131I-labeled rhBMP-2. Quantitative
analysis of the scintigraphic images revealed a sustained
release of 131I-rhBMP-2 for both doses, with different
release profiles between the two loadings. However,
around 70% of the initial dose was retained in both
implant formulations. Although low amounts of rhBMP-2
were released (2.4 6 0.8 lg in 5 weeks), histology showed
defect bridging in the high-dose implants. Release out of
the low-dose implants was not sufficient to enhance bone
formation. Implant degradation was limited in all formula-
tions, but was mainly seen in the high-dose group. Low
amounts of sustained released rhBMP-2 were sufficient to
bridge critically sized defects. A substantial amount of
rhBMP-2 was retained in the implants because of the slow
release rate and the limited degradation.  2008 Wiley
Periodicals, Inc. J Biomed Mater Res 87A: 780–791, 2008
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INTRODUCTION
Calcium phosphate (CaP) cements can be an alter-
native for autologous bone grafts, as these materials
do not only possess favorable clinical handling
properties like injectability and moldability, but also
show advantageous biological characteristics like
osteoconductivity and degradability.1–5 Nonetheless,
these osteoconductive scaffolds alone are not suffi-
cient for bone healing under deprived conditions, as
for instance in large critically sized defects. In these
situations, the extra stimulatory effect of growth fac-
tor inclusion and the subsequent osteogenic capacity
of CaP cements is an interesting approach to
enhance bone regeneration.
The transforming growth factor-b (TGF-b) super-
family comprises a large number of molecularly
related growth and differentiation factors [TGF-bs
and bone morphogenetic proteins (BMP)], each
capable of inducing bone formation.6–8 Currently up
to 20 different BMP’s have been identified.9,10 These
individual proteins are able to initiate the entire
bone formation cascade, similar to extracts of bone
matrix.8,11 Recombinant DNA biotechnology pro-
cesses offer unlimited supply and control over
purity and reproducibility by producing single BMP
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molecules such as BMP-2 and BMP-7.8 The osteo-
genic activity of recombinant human BMP-2
(rhBMP-2) has extensively been published, and its
use in humans is approved by the Food and Drug
Administration Medical Device Panel.12 RhBMP-2
induces chemotaxis of stem cells and is a differentia-
tion factor, causing mesenchymal stem cells to differ-
entiate toward an osteoblastic lineage, providing
increased numbers of osteoblasts capable of forming
bone.8,13 Its effectiveness is not only dependent on
this intrinsic activity, but also influenced by the
method of delivery, that is, the carrier material.
Carriers for rhBMP-2 increase the retention of the
protein at the treatment site for a sufficient time to
allow for activity and subsequently can provide a
scaffold for bone growth.5,14 Retention, that is, sus-
tained release of rhBMP-2 is essential because BMP
activity is tightly controlled and self-limiting through
a combination of signal-transducing and inhibit-
ing proteins.7,11 Consequently, bone induction is
observed only locally at the site where rhBMP-2 is
released and temporally when rhBMP-2 is present.
This was confirmed by Woo et al., 13 who showed
that a sustained delivery of rhBMP-2 based on poly
(DL-lactic-co-glycolic acid) (PLGA)-microspheres
resulted in faster and more complete bone repair of
rabbit calvarial defects as compared with immediate
release of rhBMP-2. CaP cement can also act as a
controlled release system by including PLGA-micro-
particles as delivery vehicle for rhBMP-2.15,16 The
polymer will degrade over time, resulting in macro-
pore formation and the release of rhBMP-2. The
macropores will subsequently allow for cellular
entry and increase the final transformation of the
implant into bone.
Regarding the amount of rhBMP-2, most studies
so far used relatively high nonphysiological doses,
which makes treatment costly and raises the issue of
safety.17 The development of better controlled re-
lease systems and the increase in knowledge of the
osteoinductive effect of low doses of rhBMP-2 are
therefore crucial topics for clinical application. It is
assumed that the use of a carrier material for
rhBMP-2, can decrease the dose of rhBMP-2 required
for sufficient bone formation.11,18,19
Based on the considerations mentioned earlier, the
aim of this study is to explore the bone regenerative
effect of composites of CaP cement and PLGA-
microparticles with a high and a five-fold lower
dose of rhBMP-2 in critically sized cranial defects in
rats. In addition, the in vivo release kinetic of the
two doses of rhBMP2 were compared, using
131I as a
tracer. We hypothesized that a low amount of
rhBMP-2 could engender sufficient bone formation
in a sustained release system, resulting in closure of
a critically sized defect.
MATERIALS AND METHODS
Materials
The CaP cement (Calcibon1, Biomet Merck, Darmstadt,
Germany) consisted of 61% a-TCP, 26% CaHPO4, 10%
CaCO3, and 3% precipitated HA. The cement powder was
sterilized by g-radiation with 25 kGy (Isotron B.V., Ede,
The Netherlands). The cement liquid applied was a filter-
sterilized (0.2-lm filter) 1% aqueous solution of Na2HPO4.
PLGA (Purasorb1, Purac, Gorinchem, The Netherlands)
with a lactic to glycolic acid ratio of 50:50 and a molecular
weight of 48.0 6 1.6 kg/mol was used for the micropar-
ticle preparation. RhBMP-2 was kindly provided by Wyeth
Pharmaceuticals, Cambridge, MA, and radiolabeled with
131I (Amersham Buchler, Braunschweig, Germany).
Radioiodination of rhBMP-2
RhBMP-2 was labeled with 131I according to the Iodo-
Gen1 method as described previously.20 For each labeling
procedure, 70 lg of rhBMP-2 was added to 20 lL 500 mM
phosphate buffer, pH 7.4, and 2.25 mCi 131I (200 mCi/mL)
in a glass vial precoated with 100 lg 1,3,4,6-tetrachloro-
3a,6a-diphenylglucouril (Pierce, Rockford, IL). The reac-
tion mixture was incubated for 10 min at room tempera-
ture and then eluted on a disposable Sephadex G25M col-
umn (PD-10, Pharmacia, Uppsala, Sweden) with PBS, 0.5%
BSA, to separate labeled rhBMP-2 from free 131I. The rele-
vant fractions were pooled. The specific activity of the 131I-
labeled rhBMP-2 was 6.5 lCi/lg. A hot/cold 131I-rhBMP-2
solution was prepared; 1:10 for the high dose and 1:1 for
the low dose rhBMP-2 implants. The radiochemical purity
of the 131I-labeled rhBMP-2 exceeded 99%, and the final so-
lution did not contain significant amounts of rhBMP-2
aggregates or degradation products.16,21
Preparation of PLGA-microparticles adsorbed
with rhBMP-2 or 131I-rhBMP-2
To prepare PLGA-microparticles a double-emulsion-sol-
vent-extraction technique ([water-in-oil]-in-water) was
used.15,22–25 This consisted of the injection of 500 lL dis-
tilled water into a tube containing a solution of 1.0 g
PLGA in 4 mL dichloromethane. The mixture was emulsi-
fied for 60 s on a vortexer. Then 6 mL 0.3% aqueous poly
(vinyl alcohol) (PVA, Acros Organics, Geel, Belgium) solu-
tion was added and emulsified for another 60 s to produce
the second emulsion. This mixture was added to 394 mL
0.3% PVA solution and 400 mL of 2% isopropylic alcohol
solution and was stirred for 1 h. The evaporation of the
solvent resulted in precipitation of the dissolved polymer
and subsequent microparticles were formed. The micropar-
ticles were allowed to settle for 15 min and the solution
was decanted. Then, the microparticles were collected
through centrifugation at 1500 rpm for 5 min, lyophilized
to dryness, and stored under argon at 2208C until use.
The size distribution of the PLGA-microparticles was
rhBMP-2 CALCIUM PHOSPHATE IMPLANTS IN RATS 781
Journal of Biomedical Materials Research Part A
determined by image analysis (Leica Qwin1, Leica Micro-
systems).
RhBMP-2 was adsorbed to the surface of the PLGA-
microparticles. Therefore 400-lL rhBMP-2 solution was
added to 500 mg PLGA-microparticles, and after 30-min
adsorption time the microparticles were lyophilized again.
The solution for the high-dose implants (610 lg rhBMP-2
per implant) contained 275 lg rhBMP-2 in PBS/BSA
[0.1%]. This dose was based on previous experience with
rhBMP-2 loaded PLGA/CaP cement implants in rats.16,21
For the low-dose implants (62 lg rhBMP-2 per implant)
55 lg rhBMP-2 in PBS/BSA [0.1%] was used. Accordingly,
131I-rhBMP-2 solutions were added to the PLGA-micropar-
ticles and lyophilized overnight. The adsorption efficiency
of rhBMP-2 onto the microparticles was 93%.16
Preparation of CaP cement implants
CaP cement powder was mixed with blank, high (610
lg per disc) or low (62 lg per disc) dose rhBMP-2, or
high/low dose 131I-rhBMP-2 PLGA-microparticles (20 wt %).
The cement was created by adding to a 2-mL syringe (BD
PlastipakTM, Becton Dickinson S.A., Madrid, Spain) with
closed tip, 1 wt % Na2HPO4 to the PLGA/CaP powder
mixture in a liquid/powder ratio of 0.35, and shaking
these components for 15 s using a mixing apparatus
(Silamat1, Vivadent, Schaan, Liechtenstein). The cement
was then immediately injected into Teflon molds with
standardized shape (discs 7.8 mm 3 1.8 mm). After setting
at room temperature overnight, the implants were re-
moved from the molds.
Surgical procedure
Fifty-two healthy young adult male Wistar rats, weigh-
ing 256 6 11 g were included as experimental animals.
National guidelines for the care and use of laboratory ani-
mals were observed. The research was reviewed and
approved by the Experimental Animal Committee of the
Radboud University.
Anesthesia was induced and maintained by isoflurane
inhalation (Rhodia Organique Fine Limited, Avonmouth,
Bristol, England). To minimize postoperative discomfort,
Fentanyl1 (Hameln Pharmaceuticals Gmbh, Hameln,
Germany) (3 mL/kg) was administered intraperitoneally
before operation and buprenorfine (Temgesic1) (Reckitt
Benckiser Health Care Limited, Schering-Plough, UK) (0.02
mg/kg) subcutaneously for 2 days after surgery.
After anesthesia the rats were immobilized on their
abdomen, and the skull was shaved and disinfected with
chloorhexidine. A longitudinal incision was made from the
nasal bone to the occipital protuberance. To minimize
pain, Lidocaine HCL 1% (B. Braun, Melsungen, Germany)
was dripped at the periosteum before incision and expo-
sure of the parietal bone. A full-thickness bone defect was
created in the dorsal part of the parietal cranium central to
the sagittal suture with a dental drill machine (Elcomed
100, W&H Dentalwerk Burmoos GmbH, Austria) with tre-
phine bur (ACE dental implant system) with an outside
diameter of 8.0 mm. The bone defect was drilled under
continuous saline cooling and with care for the underlying
dura mater and sagittal sinus. After removing the bone
segment, the defect was left empty or an implant was
placed. Although CaP cement can be injected in vivo, in
this study we choose for prehardened implants as the cra-
nial defect model did not allow for injection, because of
the thin bone rim and fragile underlying dura mater. The
periosteal tissue was closed using nonresorbable Prolene1
5-0 (Ethicon, Somerville, New Jersey) suture material. Sub-
sequently, the skin was closed with resorbable Vicryl1 4-0
(Johnson&Johnson, St. Stevens-Woluwe, Belgium). Implan-
tation time was 4 or 12 weeks. The rats were divided in
four groups (n 5 6 for each implant and time period): I
untreated control defects [Fig. 1(A)]; II plain CaP cement/
PLGA-microparticle implants [Fig. 1(B)]; III–IV CaP
cement/PLGA-microparticle implants with respectively a
high (610 lg/implant) and low (62 lg/implant) dose of
rhBMP-2. Groups III and IV with an implantation time
of 12 weeks received 131I-labeled rhBMP-2 and consisted of
eight instead of six rats.
The animals were housed individually in cages. The
intake of fluids and food was monitored in the first days
Figure 1. Cranial defect in a rat (A) with no implant and (B) with prehardened calcium phosphate cement implant.
[Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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postoperatively. Also, the animals were observed for signs
of pain, infection, and proper activity. At the end of the
implantation time the rats were sacrificed by an overdose
of CO2.
Scintigraphic analysis of in vivo
131I-rhBMP-2 release
For the in vivo 131I-rhBMP-2 release study,16 rats from
the 12-week implantation time group (n 5 8) with high-
and low-dose 131I-rhBMP-2 implants were used. Immedi-
ately after surgery (day 0) and after 1, 2, 3, 4, and 5 weeks,
the 131I activity in the implants was determined under
general isoflurane inhalation anesthesia, using a single-
head g-camera (Orbiter, Siemens Medical Systems, Hoff-
man Estates, IL) equipped with a parallel-hole high-energy
collimator. The analysis could not be continued after the
5th week, because of radioactive decay. Digital images
(25,000–65,000 counts) were acquired and quantitatively
analyzed by measuring activity in a standardized region of
interest (ROI) drawn over the implants. As a control for
100% retention, g-emission in nonimplanted reference sam-
ples was measured along with the rat implants at each
time point. The scintigraphic measurements were corrected
for radioactive decay, acquisition time, and background
activity. The retained activity of 131I-rhBMP-2 was then
expressed as a percentage of the initial activity (t 5 0). The
initial dose of rhBMP-2 as present in the samples before
implantation was determined by counting radioactivity
with a shielded well-type g-counter (Wizard, Pharmacia-
LKB, Sweden). The release of absolute amounts (lg) of
rhBMP-2 out of the implanted samples was calculated
from the percentage of retention.
Histology and histomorphometrical analysis
After sacrifice, implants with surrounding tissue were
retrieved, fixed in phosphate-buffered formaldehyde solu-
tion (pH 5 7.4), dehydrated in increasing ethanol concen-
trations (70–100%), and embedded (nondecalcified) in
methylmethacrylate. Since the 131I-half-life is assumed to
be 8 days,26 the implants with 131I-rhBMP-2 were also
included in the histological analysis after 12 weeks of im-
plantation. Thin sections (10 lm) were prepared perpen-
dicularly through the implants using a microtome with
diamond blade (Leica Microsystems SP 1600, Nussloch,
Germany). These slides were stained with methylene blue
and basic fuchsin and examined with light microscopy
(Leica Microsystems AG, Wetzlar, Germany).
In addition, all sections (with exception of the open
defects) were quantitatively scored for the percentage of
remained cement and newly formed bone using computer-
based image analysis techniques (The Leica1 Qwin Pro-
image analysis system, Wetzlar, Germany). From digital-
ized images (magnitude 1.63), the amount of remained
cement and newly formed bone were determined within
the ROI, that is, the area within the boundaries of the
implants. The amounts were expressed as a percentage of
the ROI. The measurements of three sections for each sam-
ple were averaged.
Microcomputed tomography
Before embedding in methylmethacrylate, microcom-
puted tomography (lCT) was performed on the skulls
with the empty control defects. The specimens were
wrapped in Parafilm M1 (Pechiney Plastic Packaging, Chi-
cago) to prevent drying during scanning. Then all samples
were scanned at an energy of 100 kV and intensity of 98
lA with a resolution of 14.16 lm using an aluminium filter
(1 mm) (Skyscan-1072 X-ray microtomograph, TomoNT
version 3N.5, Skyscan1, Belgium). Cone-Beam reconstruc-
tion (version 2.15, Skyscan1) was performed. All scan and
reconstruction parameters applied were identical for all
specimens. Three-dimensional images were created using
3D-creator (version 2.2h, Skyscan1) and evaluated for the
percentage of defect closure. The data were then further
analyzed by CT Analyzer (version 1.4, Skyscan1). The vol-
ume of interest (VOI) was specified as a cylindrical area
covering the created defect with a diameter of 8.02 mm
and depth of 1.2 mm. In this area, bone volume (mm3)
was determined and expressed as a percentage of the VOI.
Statistical Analysis
Statistical analysis was performed with GraphPad Instat
version 3.05 (GraphPad Software, San Diego, CA), using
an unpaired t-test with Welch correction. Differences were
considered significant at p-values less than 0.05. Pharmaco-
kinetic analysis of rhBMP-2 retention was done by non-
linear regression analysis using GraphPad1 Prism 4.03
software (GraphPad Software, San Diego, CA). Data were
fitted according to a one-phase exponential decay model.
RESULTS
Characterization of PLGA-microparticles
Figure 2 shows the size distribution of the PLGA-
microparticles prepared by a double-emulsion-
solvent-extraction technique. The average size of the
microparticles was 33 6 28 lm, as determined with
image analysis. Scanning electron micrographs
(SEM; Microscopic Imaging Center of the Nijmegen
Figure 2. Size distribution of the PLGA-microparticles
prepared by a double-emulsion-solvent-extraction technique
(group size 5 312).
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revealed a smooth spherical surface of the micropar-
ticles, occasionally with pores [Fig. 3(A)]. The micro-
particles were well incorporated and homogeneously
divided into the cement [Fig. 3(B)].
Longitudinal in vivo 131I-rhBMP-2 release
Longitudinal release kinetic over 5 weeks of im-
plantation was assessed by scintigraphic imaging of
the radiolabeled implants in vivo. All animals, except
one, underwent the scintigraphic procedure well.
One rat (high dose 131I-rhBMP-2 implant) died after
4 weeks of scintigraphic measurements, most likely
because of an anesthetic-induced respiratory distress.
Consequently, the high-dose group consisted of
seven instead of eight rats from 5 weeks onward.
The results of the 131I-rhBMP-2 retention of the
high- and low-dose implants are depicted in Figure
4(A). Both doses showed a sustained release profile,
with a considerable retention (about 70%) of rhBMP-
2 after 5 weeks of implantation. The percentage of
retention in the low-dose implants was significantly
lower (p < 0.01) as compared with the high-dose
implants in the first 4 weeks of implantation. The
data of the low-dose implants could be described
best according to a one-phase exponential release
model, with a half-life of 0.6 6 0.1 weeks and pla-
teau value of 67.9% 6 1.4%. The high-dose implants,
on the other hand, displayed an almost linear release
of rhBMP-2 within the first 5 weeks of implantation,
which is suggestive for a process approaching zero-
order kinetics. Nevertheless, we fitted the one-phase
exponential model also to the high-dose implant
data, but the calculated half-life of 7.4 6 8.4 weeks
was necessarily less accurate and a reliable estimate
for the plateau value could not be made.
The initial dose of rhBMP-2 as present in the sam-
ples before implantation was determined by count-
ing the activity in the implants in a shielded well-
type g-counter. The high-dose implants contained a
initial dose of 8.2 6 1.8 lg rhBMP-2, the low-dose
implants 1.7 6 0.4 lg. Figure 4(B) reveals the abso-
lute cumulative release of rhBMP-2 in the first
5 weeks of implantation. The lines through the data
Figure 3. Scanning electron micrograph of (A) PLGA-microparticles alone and (B) incorporated in CaP cement.
Figure 4. Longitudinal scintigraphic assessment of a high
and low dose of rhBMP-2 (A) retained in the implants (%)
and (B) the absolute cumulative release of rhBMP-2 (lg)
out of CaP cement implants. Mean and standard error of
the mean are presented for eight samples. The percentage
of retention in the low dose implants was significantly
lower (p < 0.01, unpaired t-test with Welch correction) as
compared with the high dose implants in the first 4 weeks
of implantation.
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points were again calculated according to a one-
phase exponential release model. The high-dose
group showed a higher release of rhBMP-2 (2.4 6
0.8 lg) after 5 weeks as compared with the low-dose
implants (0.6 6 0.2 lg).
As a control for 100% retention, nonimplanted ref-
erence samples were scanned simultaneously with
the rats. These eight reference samples showed an
average retention of 94 6 2% over the 5-week pe-
riod. This decrease in retention indicates that the
measured release values are somewhat overesti-
mated.
Descriptive light microscopy
A uniform tissue reaction was seen between the
specimens of the same group and implantation time.
Implantation time 4 weeks
The skulls that had received no implant showed
minimal bone formation at the defect borders and
fibrous tissue crossing the defect area [Fig. 5(A)].
In the skulls that received an implant [Fig. 5(B–
D)], the integrity of the implants was maintained for
all formulations. Minimal edge degradation was
seen in the plain- and low-dose implants, while in
the high-dose rhBMP-2 group, the implant perimeter
appeared to be more rounded. The PLGA pores
located at the external surface of the implants were
filled with bone, fibrous tissue, or bone marrow-like
tissue [Fig. 6(B)]. However, in the center of the
implant remnants of PLGA were still visible in the
pores, characterized by stained material without cells
[Fig. 6(C)]. In general, a mild inflammatory reaction
was seen as macrophages and foreign body giant
cells were only occasionally present.
Bone ingrowth was found at the edges and dura
side of the implants of all formulations, with a direct
contact of bone to cement surface [Fig. 6(A)]. Bone
formation was higher in implants with rhBMP-2 as
compared with plain implants. Moreover, in the
rhBMP-2 loaded implants and mainly in the high-
dose group, new bone was also seen at the perios-
teum side [Fig. 6(D)]. In the loaded groups, bone
remodeling was higher as compared with the plain
implants. In these groups, osteoclast-like cells were
observed degrading the implant material, while
directly opposite new bone was deposed. Bone
bridging of the defect, as characterized by a continu-
ous thin bone layer at the dura side of the skull, was
found in none of the plain implants, three out of six
low dose and four out of six high rhBMP-2 dose
implants.
Implantation time 12 weeks
After 12 weeks of implantation, the skulls with
empty control defects only showed bone formation
at the defect borders [Fig. 7(A)], confirming their
critical size.
The groups that received plain-and low-dose
implants [Fig. 7(B,C)] showed some degradation
with rounded implant edges. The high-dose im-
plants [Fig. 7(D)], on the other hand, were clearly
degraded superficially. In the periphery, ingrowth
of tissue had proceeded into the PLGA pores of the
implants, while in the center no cells were visible
[Fig. 8(A)].
Bone formation was increased for all formulations
as compared with the 4-week sections, with the lar-
gest amount of bone in the high-loaded implants.
Mature bone with bone marrow-like tissue was
deposed directly to the cement surface [Fig. 8(B)].
Bridging at the dura side was observed in two plain,
three low dose, and four high dose implants out of
totally six implants per group. In addition, the high-
dose rhBMP-2 implants also showed new bone on
the periosteum side [Fig. 8(C)].
Figure 5. Representative histological sections of cranial
defects after 4 weeks of implantation with (A) no implant,
(B) plain-CaP cement implant, (C) low-dose rhBMP-2 CaP
cement implant, and (D) high-dose rhBMP-2 CaP cement
implant. Methylene blue and basic fuchsine staining. Mag-
nifications of the boxes are depicted in Figure 6. [Color fig-
ure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Histomorphometry
The results of the quantitative measurements of
remained CaP cement and the amount of bone
formed into the implants are depicted in Tables I
and II, respectively.
After 4 weeks of implantation no significant differ-
ences in implant degradation were found between
the groups. After 12 weeks, all type of implants
showed degradation when compared with the 4-
week implantation time, though this was only signi-
ficant (p 5 0.04) for the high-dose group, with 49%
6 2% of implant remained in the ROI.
Bone formation was significantly (p < 0.01) higher
in the implants with rhBMP-2 (low and high dose) as
compared with the plain implants after 4 weeks im-
plantation. No difference in percentage of bone was
seen between the two doses at this time point. Bone
formation increased significantly in the plain- and
high-rhBMP-2 implants after 4 weeks (p < 0.01). After
12 weeks, bone formation was significantly (p 5 0.01)
higher in the high-dose group when compared with
the plain implants. There was a tendency of more
bone formation in the high dose as compared with the
low-dose implants (95% confidence interval 20.35 to
8.98; p 5 0.06, unpaired t-test with Welch correction).
MicroCT
MicroCT scanning was performed on the skulls
that received no implant to check whether the cre-
Figure 6. Magnifications of the boxes depicted in (A) Figure 5(B), showing direct bone-cement contact; (B) Figure 5(C), at
the edge of the implant; (C, D) Figure 5(D), of respectively the center and periosteum side of the implant. Methylene blue
and basic fuchsine staining. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.
com.]
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ated defect was of critical-size after 4 and 12 weeks
implantation. The results are shown in Figure 9.
Four and 12 weeks after implantation no defect
bridging was noticed in all specimens, and less than
10% bone had formed indicating that the defects
were indeed of critical size.
DISCUSSION
A reduction in the amount of rhBMP-2 required
for sufficient bone regeneration is beneficial for bone
graft substitutes from a socioeconomical and a safety
point of view. In this study, implants consisting of
composites of CaP cement and PLGA-microparticles
and a high and five-fold lower dose of rhBMP-2
were compared for their kinetics and bone regenera-
tive behavior in critically sized cranial defects in
rats. 131I-labeled rhBMP-2 showed for both doses a
sustained release pattern within the first 5 weeks,
with different release profiles between the two load-
ings. About 70% of rhBMP-2 remained in both
implant formulations. Despite the low amount of
released rhBMP-2, bridging of critically sized defects
was seen after 12 weeks of implantation in the high-
loaded implants.
RhBMP-2 has strong osteoinductive potential but
its clinical use is restrained by the lack of a suitable
delivery system, that maintains rhBMP-2 at the
defect site for sufficient time and with appropriate
dose to allow for chemotaxis of preosteoblastic cells
and their differentiation into bone forming cells.13,27
A sustained release system complying to these
requirements, might be obtained using composites of
Figure 7. Representative histological sections of cranial
defects after 12 weeks of implantation with (A) no implant,
(B) plain-CaP cement implant, (C) low-dose rhBMP-2 CaP
cement implant, and (D) high-dose rhBMP-2 CaP cement
implant. Methylene blue and basic fuchsine staining.
Magnifications of the boxes are depicted in Figure 8.
Figure 8. Magnifications of the boxes depicted in (A) Fig-
ure 7(B), showing the center of the implant; (B) Figure
7(C), at the edge of the implant; (C) Figure 7(D), of the
periosteal side of the implant. Methylene blue and basic
fuchsine staining.
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CaP cement and rhBMP-2 loaded polymeric micro-
particles. The injectable and moldable CaP cement
acts as a scaffold for bone growth and because of
polymer degradation osteoinductive rhBMP-2 is
gradually released. Subsequent to microparticle deg-
radation, macropores are formed which allow for
cellular entry, followed by transformation of the
implant into bone tissue. This study, indeed revealed
a sustained release of rhBMP-2 in the high- and
low-dose CaP cement/PLGA-microparticle implants.
This finding is in line with the study of Ruhe´ et al.,16
who also showed in vivo sustained release of
rhBMP-2 from subcutaneous CaP cement composites
when entrapped or adsorbed to PLGA-micropar-
ticles, in rats.
Remarkably, the amount of rhBMP-2 that was
retained in the implants, expressed as a percentage
of the initial dose, was significantly lower in the low
dose than in the five-fold higher dose group in
the first 4 weeks and especially in the first week of
implantation. RhBMP-2 release in the first days of
implantation is thought to derive from superficially
located PLGA-microparticles and to a lesser extent
from CaP cement located at the implant surface, as
in vitro studies showed that release from PLGA-
microparticles is significantly higher than from CaP
cement composites.15 The difference in percentage of
retention between the two groups in this study
might be explained by the PLGA-microparticle
adsorption efficiency of low and high doses of
rhBMP-2. It can be speculated that low doses of
rhBMP-2 bind stronger to microparticles than high
doses, as a high dose leads to saturation of binding
to the microparticles and subsequent translocation of
rhBMP-2 to CaP cement. Also electrostatic interac-
tions might explain the difference in retention pro-
files between high and low amounts of rhBMP-2.28
RhBMP-2 was diluted in a solution containing BSA
to which it can bind, and the resulting complex is
negatively charged. Low doses of rhBMP-2 are sur-
rounded by higher amounts of BSA than high doses,
and will thereby be easily released from negatively
charged CaP cement implants. More detailed studies
are needed to determine the mechanism of this com-
plex phenomenon.
After 1 week, retention in the low-loaded implants
was more or less stabilized, while the high-dose
implants showed an almost linear release, approach-
ing the characteristics of zero-order kinetics. The
relatively short half-life of 131I (8.02 days)26 allowed
histological analysis of the implants in the same rats
that received radiolabeled rhBMP-2. The histological
analyses at 4 weeks implantation indicated that CaP
cement degradation was higher in the high-loaded
group, supporting the suggestion that rhBMP-2
release from 1 week on was degradation dependent.
So far we do not know any previous studies that
have dealt with the kinetics of differently loaded
CaP cement implants, and that were able to combine
release and histological data. The influence of
rhBMP-2 to implant degradation, which was mainly
seen in the high-dose group, is consistent with previ-
ous investigations and might be explained by the
TABLE I
The Percentage of Remained Implant in the ROI as
Determined with Histomorphometry
RhBMP-2 Implant
% Implant Plain Implant Low Dose High Dose
4 weeks 58 6 4 59 6 3 56 6 6
12 weeks 55 6 3 55 6 5 49 6 2*
Data represent the mean and standard deviations. High-
dose rhBMP-2 implants significantly (*) degraded after
12 weeks of implantation (unpaired t-test with Welch
correction).
TABLE II
The Percentage of New Bone in the ROI as Determined
with Histomorphometry
RhBMP-2 Implant
% Bone Plain Implant Low Dose High Dose
4 weeks 5.5 6 0.4 8.2 6 1.3* 8.1 6 1.3*
12 weeks 10 6 3* 11 6 4 16 6 2**
Data represent the mean and standard deviations. After
4 weeks, the percentage of bone in the low- and high-dose
rhBMP-2 implants was significantly (*) higher as compared
with plain implants. After 12 weeks, the difference
between plain- and high-dose rhBMP-2 implants was sig-
nificant (**), and there was a tendency (p 5 0.06) of more
bone formation in the high as compared with the low-dose
rhBMP-2 implants. Comparing the 4- and 12-week implan-
tation time, plain- and high-dose implants showed a sig-
nificant (*) increase in percentage of bone (unpaired t-test
with Welch correction).
Figure 9. Micro-CT images of a cranial defect (8 mm after
(A) 4 weeks and (B) 12 weeks of implantation, with the
percentage of bone formed in the defect depicted below.
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regulation of osteoclastic precursors by the biological
action of rhBMP-229,30 or by new bone marrow for-
mation where osteoclastic precursors reside.17
The implants were placed in 8-mm cranial defects
in rats. Untreated defects clearly showed to be
critically sized, which corroborates with previous
studies.31,32 Plain composites of CaP cement/PLGA-
microparticles improved bone growth by providing
an osteoconductive scaffold, but the combination of
osteoconduction and osteoinductive rhBMP-2 turned
out to be capable to bridge the critical defect. Bone
formation in all implant formulations was not only
located at the defect edges, but also at the dura side.
This is consistent with preceding investigations,31,32
demonstrating that the dura mater delivers precur-
sor cells involved in rhBMP-2-induced bone forma-
tion. In addition, Wang and Glimcher32 performed
3H-thymidine labeling studies, showing that subse-
quent to the dura mater, preosteoblasts were derived
from the connective tissue covering the defects. In
this study, such periosteal bone formation was only
seen in the high-loaded implants.
The main aim of this study was to examine
whether a low dose of rhBMP-2 could be as effective
in bone regeneration as a generally used higher
dose,6,27,33–37 when released in a sustained manner.
As mentioned earlier, this study allowed for the
combination of release and histological data. Histol-
ogy showed significantly more bone in the implants
loaded with a high than with a low dose of rhBMP-2
after 12 weeks. Nevertheless, only 2.4 6 0.8 lg
rhBMP-2 was released in 5 weeks of implantation.
The release profile thereafter could not be measured,
but is supposed to follow implant degradation. At
12 weeks of implantation, degradation of the high-
loaded implants was limited to about 50%, which
confirms that the total released dose did not reach 5
lg, and that high doses of rhBMP-2 are not a prereq-
uisite to obtain enhanced bone regeneration. The
dose required for improved bone regeneration
should overcome the tight regulation of osteogenic
and inhibiting factors7,11 and should trigger suffi-
cient amounts of BMP responsive cells, that is the
critical cell density, that can generate the desired
bone formation.14 Apparently, our high-dose
implants complied with these necessities. The low-
dose implants, on the other hand, showed signifi-
cantly more bone formation after 4 weeks implanta-
tion as compared with the plain implants. However,
this difference disappeared after 12 weeks, suggest-
ing that the critical cell density was not reached and
that the required dose for enhanced bone formation
is bound to a threshold. Although this study shows
that low amounts of rhBMP-2 are sufficient to
increase bone regeneration, no clear extrapolation of
absolute values as required in larger animal models
and humans can be made, because higher animal
species need larger doses of rhBMP-2 to obtain equal
effects as in rodents.5,6,11,14 Nonetheless, this study
provides a proof of principle that the required rela-
tive amounts of rhBMP-2 can be reduced by using a
sustained release system, as we were able to identify
the amounts of rhBMP-2 that were actually released
and to combine these data with histology.
It has to be noted that the rhBMP-2 release as
assessed by scintigraphic imaging is somewhat over-
estimated, as the nonimplanted reference samples
showed a decrease in retention. However, longitudi-
nal scintigraphy was found to be reliable in previous
studies,16,21 and the overestimation of rhBMP-2 re-
lease does not conflict with the conclusion that low
doses of rhBMP-2 are capable of inducing enhanced
bone formation.
Both implant formulations and the low-dose group
in particular, showed a considerable retention of
rhBMP-2. This might be explained by the high bind-
ing affinity of rhBMP-2 for CaP cement,5,33 but also
by the limited PLGA-microparticle degradation. In
this study, no cells were found in the center of the
implants after 4 and 12 weeks of implantation. This
is in contrast with the study of Ruhe´ et al.,38 who
used smaller implants of the same material, placed
subcutaneously, and in noncritically sized cranial
defects in rats. Throughout these implants tissue
ingrowth was seen, confirming degradation of the
PLGA. Evidently, in our critically sized samples
PLGA was entrapped in the center of the implant
and thereby withdrawn from necessary fluids for
degradation, which may explain the limited cellular
entry. Besides larger implant size, in this study the
dimension of the microparticles was also smaller as
compared with the samples in the study of Ruhe´
et al. (33 6 28 lm and 66 6 25 lm, respectively).
This narrow pore diameter may have hindered new
tissue infiltration. In conclusion, although this study
revealed that low amounts of rhBMP-2 are sufficient
to enhance bone regeneration, high amounts of
rhBMP-2 were retained in the CaP cement implants.
Complete release of rhBMP-2 and improved implant
degradation has to be the goal of future studies,
which perhaps can be obtained by using more rap-
idly degrading low-molecular weight PLGA-micro-
particles or particles made from other polymers.
A complex factor in rhBMP-2 bioactivity concerns
the way the protein becomes activated. It has been
assumed that rhBMP-2 not only acts after being
released, but also when it is presented to the target
cells in a ‘‘bound’’ form.39–41 According to this
theory, retained surface bound rhBMP-2 could have
influenced the amount of bone formation in this
study. The extent of this contribution is difficult to
determine, as no techniques are available to differen-
tiate between bound and released forms of rhBMP-2
in vivo.
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CONCLUSIONS
PLGA/CaP cement composites are sustained
release carriers for rhBMP-2, in which the loading of
rhBMP-2 influences the release profile and the
release is degradation dependent. In this sustained
release system, the controlled release of a low dose
(2.4 6 0.8 lg in 5 weeks) of rhBMP-2 was found to
be sufficient to induce bone bridging of critically
sized skull defects. Relatively high amounts of
rhBMP-2 retained in the composites, because of the
slow release rate and limited PLGA-microparticle
degradation.
The authors thank Cathelijne Frielink and Huub Rennen
for their help with the 131I-rhBMP-2 release study. RhBMP-
2 was kindly provided by Wyeth Pharmaceuticals (Cam-
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